Slide 1: Fourth Quarter 2023 Earnings Presentation
ANGIODYNAMICS Fourth Quarter 2023 Earnings Presentation July 12, 2023 1
Slide 2: Forward-Looking Statement
Forward-Looking Statement Notice Regarding Forward-LookingStatements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, ca
Slide 3: Corporate Developments – Q4 and FY23
Corporate Developments – Q4 and FY23 Continued focused investment in our 3 key Med Tech platforms: Auryon, Thrombus Management & NanoKnife Q4 revenue growth of 4.7% • Med Tech up 17.2%; Med Device up 0.3% • $11.8 million in Auryon sales, growth of 22.0% YOY • Mechanical Thrombectomy (AngioVac and Al
Slide 4: FY24 Guidance
FY24 Guidance Guidance* Revenue $328 - $333 million Gross Margin 50.0% - 52.0% Med Tech 63.0% – 65.0% Med Device 43.0% - 45.0% Adjusted EPS ($0.28) – ($0.34) * FY23 pro forma results excluding the divested assets were $306.3 million for revenue, 50.5% for gross margin and adjusted loss per share of
Slide 5: Q4 and FY23 Results (unaudited)
Q4 and FY23 Results (unaudited) $ in thousands (except per share data) Q4 FY23 Q4 FY22 Change FY23 FY22 Change Revenue $91,074 $86,998 4.7% $338,752 $316,219 7.1% Med Tech $26,494 $22,611 17.2% $96,687 $78,717 22.8% Med Device $64,580 $64,387 0.3% $242,065 $237,502 1.9% United States $74,439 $73,704
Slide 6: Q4 and FY23 Results
Q4 and FY23 Results Q4 Revenue Contribution Full Year Revenue Contribution Med Tech Med Tech Med Device Med Device Q4 FY22 Q4 FY23 FY22 FY23 26% 29% 25% 29% Med Tech 74% Gross Margin 71% 71% 75% 64.1% Q4 Revenue Growth Full Year Revenue Growth Q4 FY22 Q4 FY23 FY22 FY23 Med Device Gross Margin 46.4%
Slide 7: Sales Comparison to Prior-Year Periods
Sales Comparison to Prior-Year Periods Med Tech Q4 FY23 FY23 Auryon 22.0% 41.2% Thrombus Management* 7.8% 8.9% AngioVac (8.3%) (8.2%) AlphaVac** 86.9% 232.2% NanoKnife® Disposables 28.0% 27.1% NanoKnife® Capital 13.0% (9.4%) Med Device Q4 FY23 FY23 Core Peripheral 2.5% 7.9% Venous (6.4%) (12.4%) PIC
Slide 8: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation 8
Slide 9: Reconciliation of GAAP to Non-GAAP Adjusted Net Income (Loss) and EPS
Reconciliation of GAAP to Non-GAAP Adjusted Reconciliation of Net Loss to Adjusted EBITDA Net Income (Loss) and EPS (in thousands, except per share data) (in thousands) (1) Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and
Slide 10: Reconciliation of GAAP to Non-GAAP Pro Forma FY23 Results
Reconciliation of GAAP to Non-GAAP Pro Reconciliation of GAAP to Non-GAAP Pro Forma FY23 Results Forma Adjusted Net Loss and EPS (in thousands, except per share data) (in thousands, except per share data) 10